tradingkey.logo

BRIEF-Biogen And Stoke Therapeutics Enter Into Collaboration

ReutersFeb 18, 2025 3:00 PM

- Biogen Inc BIIB.O:

  • BIOGEN AND STOKE THERAPEUTICS ENTER INTO COLLABORATION TO DEVELOP AND COMMERCIALIZE ZOREVUNERSEN FOR THE TREATMENT OF DRAVET SYNDROME, A RARE GENETIC EPILEPSY ASSOCIATED WITH REFRACTORY SEIZURES AND NEURODEVELOPMENTAL IMPAIRMENTS

  • BIOGEN INC - PHASE 3 STUDY OF ZOREVUNERSEN TO INITIATE IN Q2 2025

  • BIOGEN INC - STOKE RETAINS EXCLUSIVE RIGHTS FOR ZOREVUNERSEN IN US, CANADA, MEXICO; BIOGEN GETS REST OF WORLD

Source text: ID:nBwbh3DmPa

Further company coverage: BIIB.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI